Evaluation of a human adenovirus viral load assay using the Altona RealStar® PCR test.

Journal: Diagnostic microbiology and infectious disease
PMID:

Abstract

This study evaluated the performance of the Altona Diagnostics RealStar® Adenovirus Research Use Only (RUO) real-time PCR reagents for HAdV quantitation in plasma samples from immunodeficient patients. The assay was linear from 2.30-9.17 log copies/mL (coefficient of determination; R=0.998) with limits of detection and quantification of 2.19 log and 2.30 log copies/mL (>95% positivity rate), respectively. Assay precision was highly reproducible with coefficients of variance ranging from 0% to 4.7%. A comparison of 66 matched samples showed good agreement (R=0.845) between the Altona and the reference laboratory assay, with an average negative bias (-0.24 log copies/mL). Genotyping analysis demonstrated that HAdV species B and C accounted for 77% of the positive samples. A significant (≥0.9 log) difference in quantitation between both tests was found for three HAdV types (HAdV types A12, B14 and F41). In conclusion, the Altona RealStar® test is a reliable and sensitive assay for HAdV DNA quantitation.

Authors

  • Hanna Rennert
    Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY. Electronic address: har2006@med.cornell.edu.
  • Girish Ramrattan
    Department of Pathology and Laboratory Medicine, New York-Presbyterian Hospital, New York, NY.
  • Zhengming Chen
    Division of Biostatistics and Epidemiology, Department of Healthcare Policy and Research, New York, NY.
  • Patrick McIntire
    Department of Pathology and Laboratory Medicine, New York-Presbyterian Hospital, New York, NY.
  • Alber Michaeel
    Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY.
  • Anna Khazanova
    Department of Pathology and Laboratory Medicine, New York-Presbyterian Hospital, New York, NY.
  • Stephen G Jenkins
    Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY.
  • John Sipley
    Department of Pathology and Laboratory Medicine, New York-Presbyterian Hospital, New York, NY.